Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Guilty Ruling for Ono Employees Now Final and Binding: Onoact Case
A guilty ruling delivered last month to two employees of Ono Pharmaceutical over their bribery charges tied to Onoact (landiolol), the company’s anti-arrhythmic drug, became final and binding on July 14, according to people familiar with the matter. On June…
To read the full story
Related Article
- Maker FTC Issues “Warning” to Ono over Onoact Bribery Case
December 16, 2021
- JPMA Suspends Ono’s Membership over Onoact Bribery Case
September 17, 2021
- Probe Panel Urges Ono to Establish Foundation to Handle Scholarship Donations after Bribery Case
August 16, 2021
- 2 Ono Employees Found Guilty for Onoact Bribery Charges; Scholarship Donation in Spotlight
June 30, 2021
- Jail Terms Sought for 2 Ono Employees over Onoact-Tied Bribery Charges
June 1, 2021
- 2 Ono Employees Admits Bribery Charges over Onoact Prescriptions
May 17, 2021
- Ono President Apologizes to JPMA After 2 Employees Are Indicted for Bribery
February 22, 2021
- Ono Sets Up Investigation Panel on Bribery Issue
February 19, 2021
- Ono Apologizes over Arrest of 2 Employees on Bribery Allegations
January 29, 2021
BUSINESS
- GSK Files Hep B Drug in Japan as First Global Submission
February 27, 2026
- Astellas Doubles Labor Productivity Since FY2020, Credits Organization Rejig
February 27, 2026
- Sumitomo Regains DSP-0187 Rights as Jazz Calls Off Deal
February 27, 2026
- Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
February 27, 2026
- Daiichi Sankyo Chair Manabe to Step Down in June
February 27, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…